Palvella Therapeutics (PVLA) Free Cash Flow (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Free Cash Flow for 14 consecutive years, with -$10.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 61.05% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$29.1 million (down 76.53% YoY), while the FY2025 annual figure was -$25.0 million, down 130.68% from the prior year.
• Free Cash Flow eased to -$10.9 million in Q1 2026 per PVLA's latest filing, from -$4.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $20.5 million in Q4 2023 and bottomed at -$23.0 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$7.2 million across 5 years, with a median of -$7.8 million in 2022.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 246.74% — and 2025, when it sank 514.16%.
• Palvella Therapeutics' Free Cash Flow stood at -$13.9 million in 2022, then jumped by 246.74% to $20.5 million in 2023, then slumped by 126.36% to -$5.4 million in 2024, then climbed by 9.03% to -$4.9 million in 2025, then slumped by 122.18% to -$10.9 million in 2026.
• Business Quant data shows PVLA's Free Cash Flow at -$10.9 million in Q1 2026, -$4.9 million in Q4 2025, and -$7.9 million in Q3 2025.